Phialogics
Key Facts
| Invested since | 2022 |
| Based in | International |
About the company
Phialogics is an innovative start-up in the field of autoimmune diseases. Founded in 2021 by a team of widely recognized experts in protein engineering and immunology, the company based in Basel (CH) and Heidelberg (GER) is committed to making a decisive contribution to the autoimmune disease space. The founding team is backed by strong Scientific Advisory and Supervisory Boards, which puts the company in a good position to move fast on the lead candidate and develop novel biologics.
Do you want to
know more about this company?
Phialogics in the news
Zum Artikel
Phialogics secures pre-seed financing for Next-Gen IgV Therapeutics to modulate immune responses in inflammatory diseases
More startups from Life Sciences
Exit
KSK Diagnostics GmbH uses its isothermal amplification technology, KDx rITA®, for the development of molecular point-of-care tests to identify pathogens and antimicrobial resistance within 30 minutes. This significantly reduces the …
To the complete profileof KSK Diagnostics
Exit
Development of antibody conjugate-based cancer therapeutics for solid tumors with high unmet needs that are otherwise difficult to treat Problem: Solid cancers are still very difficult to treat. Most treatments …
To the complete profileof Emergence Therapeutics
Intelligent fluids GmbH is designing innovative high performance cleaning fluids for industrial application that are unique in the world. These intelligent fluids® are based on a groundbreaking, patented technology that …
To the complete profileof intelligent fluids
Resolve Biosciences is creating solutions which offer the power of Molecular Cartography enabling scientists to gain valuable insights at subcellular resolution, across vast numbers of biomolecules (RNA, DNA, proteins) to …
To the complete profileof Resolve Biosciences
Lindis Blood Care is developing a medical device to be used in oncology for the operation of tumours in order to open up the possibility of self-blood administration of blood …
To the complete profileof Lindis Blood Care
O11 biomedical, a visionary medical technology start-up that emerged as part of BioTex at RWTH Aachen University/ University Hospital Aachen 2022, aims to improve survival rates and quality of life …
To the complete profileof O11 biomedical
Exit
Lipocalyx develops transfection reagents. Our Viromers® are polymers emulating a viral mechanism for cell entry. The company provides reagents and currently establishes services for pharmaceutical applications.
To the complete profileof Lipocalyx
Exit
Provecs Medical develops novel products from its platform technology for cancer treatment by specific activation of the immune system. Exit since July 2015.
To the complete profileof Provecs Medical
miRdetect is a biotechnology company founded in 2016, with the aim to revolutionise cancer diagnostics. The focus is on development, production and distribution of in-vitro diagnostics based on molecular diagnostic …
To the complete profileof miRdetect
Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases, such as liver fibrosis, cirrhosis and liver cancer (hepatocellular carcinoma, HCC). Alentis has in-licensed platform technologies and monoclonal …
To the complete profileof Alentis
Refoxy is the first biotech company purposely developing FOXO3 activators to leverage the therapeutic effects related to this master regulator of biological homeostasis. Refoxy’s discovery platform, F.act finder (FOXO activator …
To the complete profileof Refoxy Pharma
Coramaze Technologies develops an innovative, highly differentiated, transcatheter tricuspid valve repair system, called TriPair. Headquartered in Germany with an R&D hub in Israel, we promote health equity by offering a …
To the complete profileof coramaze